The effect of daily consumption of probiotic yogurt on liver enzymes, steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized clinical trial

Sara Ebrahimi-Mousavi1,2, Seyed Moayed Alavian3, Amir Ali Sohrabpour4, Fatemeh Dashti1,2, Kurosh Djafarian2 and Ahmad Esmailzadeh5,6,7*

Abstract

Background: Given the increasing prevalence of non-alcoholic fatty liver disease, it is necessary to find an easy and cost-effective method in its management and treatment. Probiotics are a group of living microorganisms that might affect NAFLD through the intestinal-liver axis. The present clinical trial aims to examine the effect of probiotic yogurt consumption on liver enzymes, steatosis and liver fibrosis in patients with NAFLD.

Methods: Sixty-eight patients with NAFLD will be recruited in this study. After block matching for sex, BMI and age, patients will be randomly assigned to receive 300 g/d probiotic yogurt containing $10^6$ cfu/g of Lactobacillus acidophilus and Bifidobacterium lactis strains or 300 g/d plain yogurt daily for 12 weeks and those in the control group would receive similar amounts of plain yogurts. Weight, height, and waist circumference will be measured at study baseline and after the intervention. Biochemical indicators including plasma glucose, serum insulin, lipid profile, liver markers (ALT, AST and GGT) will be examined at study baseline and at the end of the trial. Insulin resistance and insulin sensitivity will be determined using the HOMA-IR and QUICKI equation. The degree of steatosis and hepatic fibrosis will also be assessed at the beginning and end of the intervention by the same gastroenterologist using elastography with fibroscan.

Discussion: Probiotics have been suggested as a new strategy in the management of NAFLD. Their effects might be mediated through intestinal microbiota modification and production of short-chain fatty acids. Consumption of probiotic-enriched foods, rather than their supplements, might be a cost-effective method for long-term use in these patients. In case of finding the beneficial effects of probiotic yogurt consumption in the current clinical trial, its inclusion in the dietary plan of NAFLD patients can be recommended.

Trial registration This clinical trial was registered in Iranian Registry of Clinical Trials (www.irct.ir) at 2021-04-19 with code number of IRCT20210201050210N1.

*Correspondence: a-esmailzadeh@tums.ac.ir
5 Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, P.O. Box 14155-6117, Tehran, Iran
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
**Background**

Non-alcoholic fatty liver disease (NAFLD) is defined as an exacerbation of the triglyceride content in hepatocytes (greater than 5% of liver weight) without excessive alcohol consumption [1]. NAFLD is the most common type of chronic liver disease in the world which might result in simple steatosis, non-alcoholic steatohepatitis (NASH) and fibrosis. These complications can eventually progress to cirrhosis or liver carcinoma [2]. The general prevalence of NAFLD, based on ultrasound screening, is estimated to be 20–30% [3]. In Asia, it has been reported that 15 to 40% of population are affected [4]. According to a meta-analysis, 32% of population in the Middle East and 34% in Iran suffer from this condition [5].

Although weight loss has been the most effective strategy to manage this condition [6–8], dieting for weight loss has had little success in obese people in the long run. Therefore, it is necessary to find complementary therapies to control this condition. The composition of gut microbiota has recently gained great attention in several chronic diseases including fatty liver. Gut microbiota seem to affect this condition through various pathways including increased ethanol production, increased lipopolysaccharide (LPS) release and activating inflammatory cytokines [9, 10]. Therefore, modification of gut microbiota through probiotics might be a new strategy for effective management of NAFLD [11–13]. Earlier studies have shown the efficacy of probiotic supplements in improving levels of liver enzymes [14–17], lipid profiles [14, 18], inflammatory factors [19–21], steatosis [16] and fibrosis [16]. However, due to the high cost of supplements, low access and the possibility of inducing infection and inflammation by their high dosages in long time [14–17], taking probiotics in the context of foods might be a superior choice than supplements. Probiotic foods also contain other nutrients that can be effective in liver health. In addition, findings based on supplements of probiotics may not be generalizable to all patients because of their short-term high dosage use in clinical trials [22–26].

Despite several studies about the effect of probiotic supplements on liver health, limited investigations have assessed the effect of probiotic-enriched foods. In a clinical trial on 102 NAFLD patients, consumption of symbiotic yogurt for 24-week resulted in a significant reduction in liver enzymes and steatosis [27]. Nabavi et al., in a study on 62 patients with NAFLD, administered probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium for 12 weeks and found a significant reduction in liver fat and enzymes [28, 29]. None of these studies have examined the effect of such interventions on liver fibrosis. In addition, both studies have used ultrasound, rather than fibroscan, to examine liver fat, which might be subject to errors due to subjective decisions. Also, as evidenced in the latest systematic review and meta-analysis, further studies are needed to investigate the effect of probiotics on liver fibrosis, and since studies on probiotic foods are limited. Therefore, the aim of this study was to evaluate the effect of probiotic yogurt consumption on liver enzymes, steatosis and liver fibrosis in patients with NAFLD.

**Patients and methods**

**Participants**

This study will be a parallel randomized clinical trial (CRT) that will be conducted in Tehran, Iran, in 2021. The sample size was calculated by considering the type 1 error of 5%, the study power of 80% and the hepatic steatosis levels [30] (based on CAP) as a key variable based on data from previous studies. Considering the mean difference in hepatic steatosis levels of 2 dB/mL between the two groups [12], using the suggested formula for parallel clinical trials, we will need 28 patients in each group. However, by taking a possible drop-out of 20% into account, we will recruit 34 patients in each group based on the study inclusion criteria. Outpatients with NAFLD will be recruited from private clinics in Tehran, Iran. The diagnosis of NAFLD will be done by a gastroenterologist based on examination with a fibroscan. The study is ethically approved by the Bioethics Committee of Tehran University of Medical Sciences, Tehran, Iran, and is registered in the Iranian Registry of Clinical Trials website (http://www.irct.ir).

**Inclusion criteria**

In this study, we will recruit patients with NAFLD, whom condition was approved by a gastroenterologist using fibroscan examination. Individuals aged 20–60 years with a body mass index between 25 to 35 kg/m² that have a fixed plan for medication use during the last 3 months will be included in the current study.

**Non-inclusion criteria**

We will not include smokers, those with a history of alcohol use, pregnant or lactating women or those planning to get pregnant in the next three months, individuals with pathologic conditions affecting the liver, including acute and chronic hepatitis, viral
hepatitis, liver transplantation, autonomic hepatitis, hemochromatosis, primary biliary cirrhosis or Wilson's disease, antitrypsin deficiency, thyroid disease and lactose intolerance. In addition, patients who were taking antibiotics and medications affecting serum lipids as well as those taking multivitamin-minerals during the previous month will not be included. Use of any probiotic products during the last two months will be another non-inclusion criteria.

Exclusion criteria
We will exclude patients who are on a specific diet throughout the study, those who are consuming alcohol and/or tobacco as well as individuals who are taking multivitamin-minerals throughout the study. In addition, any changes in the medications during the study will also be a criterion for exclusion.

Study design and intervention
A flowchart of the study design is shown Fig. 1. Flow-diagram of study process is shown in Fig. 2. In the first phase of this study, we will screen 300 patients with NAFLD based on the inclusion criteria mentioned above. Then, those who meet the criteria will be included in the study. All participants will be asked to complete and sign the written informed consent. Before the start of intervention, all study participants will be in a 2-week run-in period, during which four 24-h food recalls (two working days and one non-working day) will be used to collect dietary information. In addition, subjects will be requested to record their physical activity for two days (one working day and one weekend day) during this period. Further information about demographic characteristics, past medical history, medication use as well as socioeconomic status (SES) will be collected in this period through the use of a comprehensive questionnaire in a face-to-face interview. Anthropometric indices,
blood pressure, liver enzymes, insulin resistance, hepatic steatosis, liver fibrosis and lipid profile will be evaluated at study baseline. Then study participants will be classified into blocks based on age (20–40/ 40–60 years old), sex (male, female) and BMI (25–30/ 30-35 kg/m²). Therefore, the size of each block will be 2 people with the same age, sex and BMI. These participants will then be randomly assigned into intervention and non-intervention groups. Randomization will be done by a third person, who is not aware of the study aims and groups. The first person (say A) in a block will be assigned into the intervention group and the second person (say B) in that block will be assigned into the control group. All participants, study personals and laboratory staffs will be blind to the intervention. Participants in the intervention group will consume 300 g/d of probiotic yogurt containing $10^6$ cfu/g of Lactobacillus acidophilus and Bifidobacterium lactis strains for 12 weeks, while participants in the control group will consume 300 g/d of plain yogurt daily (without any added probiotics) for 12 weeks. Yogurt packages will be distributed to participants every two weeks. The appearance, packaging and taste of yogurts will be the same. Quality control of these yogurts in terms of colony forming units of live bacteria and other nutritional values will be evaluated before the study. In order to comply with the ethical requirements in research, all patients will receive a weight loss diet after ending the study. Participants will be asked not to change their routine lifestyle, dietary habits, and medicines throughout the study. All study outcomes will be examined again at the study end. The study was designed according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 shown in Fig. 3.

**Adherence**

Individuals will be asked to record their daily intake of probiotic or conventional yogurt in a checklist given them by researchers. To increase compliance and prevent forgetting about daily consumption of probiotic or conventional yogurt, participants will receive short messages on their cell phones every day as a reminder. In addition, each time yogurt packages are delivered, patients will be requested to return empty packages of consumed ones. To ensure the consumption of yogurts by the study

---

### STUDY PERIOD

| TIMEPOINT** | Allocation | Post-allocation | Close-out |
|-------------|------------|-----------------|-----------|
| 0 | Baseline | WK2 | WK4 | WK6 | WK8 | WK10 | WK12 | WK13 |

**ENROLMENT:**
- Eligibility screen: X
- Informed consent: X
- General characteristics: X
- Type and dosage of medications: X
- Allocation: X

**INTERVENTIONS:**
- Probiotic yogurt group
- Control group

**ASSESSMENTS:**
- Dietary recalls: X X X X X
- Physical activity recalls: X X X
- Degree of fibrosis and steatosis: X X X
- Anthropometric measures: X X X
- Hematological assessments: X X X
- Blood pressure: X X X
- Consultation with study coordinator: X X X X

*Fig. 2 Flowchart of enrolment, intervention and assessments. NAFLD: non-alcohol fatty liver disease, WK: week. The “X” refers to time of allocation, intervention and assessment of variables*
| Section/Item | Item No | Description | Addressed on page number |
|-------------|---------|-------------|--------------------------|
| **Administrative information** | | | |
| Title | 1 | Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym | 1 |
| Trial registration | 2a | Trial identifier and registry name. If not yet registered, name of intended registry | 3 |
| | 2b | All items from the World Health Organization Trial Registration Data Set | 1 |
| Protocol version | 3 | Date and version identifier | 1 |
| Funding | 4 | Sources and types of financial, material, and other support | 13 |
| Roles and responsibilities | 5a | Names, affiliations, and roles of protocol contributors | 1 |
| | 5b | Name and contact information for the trial sponsor | 1 |
| | 5c | Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities | 13 |
| | 5d | Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee) | 13 |
| **Introduction** | | | |
| Background and rationale | 6a | Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention | 5 |
| | 6b | Explanation for choice of comparators | 6 |
| Objectives | 7 | Specific objectives or hypotheses | 6 |
| **Trial design** | 8 | Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) | 6 |
| **Methods: Participants, interventions, and outcomes** | | | |
| Study setting | 9 | Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained | 6 |
| Eligibility criteria | 10 | Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) | 7 |
| Interventions | 11a | Interventions for each group with sufficient detail to allow replication, including how and when they will be administered | 7-8 |
| | 11b | Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) | 7 |
| | 11c | Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) | 7-8 |
| | 11d | Relevant concomitant care and interventions that are permitted or prohibited during the trial | 8 |
| Outcomes | 12 | Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended | 9-12 |
| Participant timeline | 13 | Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) | Fig. 3 |

**Fig. 3** Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) chart of the enrollments and assessments during randomized controlled
### Methods: Assignment of interventions (for controlled trials)

| Allocation: |  |
| --- | --- |
| **Sequence generation** 16a | Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions |
| **Allocation concealment mechanism** 16b | Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned |
| **Implementation** 16c | Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions |
| **Blinding (masking)** 17a | Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how |
| 17b | If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial |

### Methods: Data collection, management, and analysis

| Data collection methods 18a | Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol |
| **Data management** 19 | Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol |
| **Statistical methods** 20a | Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol |
| 20b | Methods for any additional analyses (eg, subgroup and adjusted analyses) |
| 20c | Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation) |

### Methods: Monitoring

| Data monitoring 21a | Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed |
| 21b | Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial |
| **Harms** 22 | Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct |
| **Auditing** 23 | Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor |

### Ethics and dissemination

| Research ethics approval 24 | Plans for seeking research ethics committee/institutional review board (REC/IRB) approval |
| **Protocol amendments** 25 | Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators) |
participants, and not their family members, additional packages of conventional yogurts will be given to them for probable family members’ use.

**Outcomes**
The outcomes of the present clinical trial would be assessment of steatosis, fibrosis, serum liver enzyme levels including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), Gamma-glutamyl transferase (GGT). Systolic (SBP) and diastolic blood pressure (DBP), lipid profiles including high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), serum triglycerides (TG) fasting blood sugar (FBS), fasting insulin and glucose hemostasis will also be considered. Weight and BMI will also be assessed. All these measurements will be assessed at study baseline and the end of trial.

**Dietary intake and physical activity assessment**
In order to ensure lack of change in dietary intakes of participants during the study, we will collect dietary intake data through the use of a 24-h dietary recall every three weeks throughout the study. These dietary recalls will be distributed through the week days to cover two working days and two weekends. Due to COVID-19 pandemic, dietary recalls will be completed through phone calls, not by face-to-face method. In these phone calls, participants will be asked to report their dietary intakes in a preceding day based on household measures. All reported foods in these recalls will then be converted to grams using available booklets. The average intake based on four dietary recalls will be considered in the analysis.

Participants will be asked not to change their physical activity during the trial. To make sure about this, we will request study subjects to record their physical activity in four separate days throughout the study including two working days and two weekends. All participants will be instructed how to record the type, intensity and time spent in each activity in a certain form that will be given to them at the study baseline. In order to process the physical activity records, we will use earlier published guidelines about MET-h/day values for each type of physical activity, in which we will consider the time spent for a certain physical activity by each participant. All records would be reviewed immediately to find possible errors and the problems will be resolved by interview.

**Assessment of hepatic steatosis and fibrosis**
Hepatic steatosis and fibrosis among all participants will be examined by transient elastography with fibroscan by the same gastroenterologist at the beginning and end
of the study. Patients will be asked to lie down on their back and place the right hand above their head. Then the probe will be placed on the right side of the liver in patients’ intercostal area. The results of liver fibrosis will be expressed as Kilopascal (Kpa). The interpretation of fibrosis assessment results will be based on META VIR Score [31]. The controlled attenuation parameter (CAP) test will be used to assess steatosis and the results will be reported in dB/m. CAP results will vary between 100 and 400 dB/m.

Biochemical assessment
To assess the level of liver enzymes (ALT, AST, GGT), blood sugar and lipid profiles (including total cholesterol, serum triglyceride and HDL cholesterol), 10 cc of intravenous blood samples will be collected after 10–12 h of fasting. Blood samples are centrifuged for 10 min at 2606.8 G and 4 °C to separate serum samples. The level of ALT and AST enzymes will be determined by photometry (Pars Azmoun) proposed by the IFCC (International Federation of Clinical Chemistry) method. GGT levels will also be assessed using the calorimetric-kinetic method proposed by the IFCC. Fasting blood glucose (FBS) levels will be measured by glucose oxidase and fasting insulin levels will be measured by ELISA method. Serum concentrations of total cholesterol and triglycerides will be measured by laboratory methods using enzymes such as cholesterol esterase, cholesterol oxidase and glycerol phosphate oxidase, respectively, using standard kits. HDL-C will be measured after deposition of apolipoprotein-B, which contains lipoproteins with phosphotungstic acid. LDL-C will be calculated from the values of TC, TG, HDL_C by the formula of Friedwald [32].

Glucose homeostasis assessment
Homeostatic Model Assessment of Insulin Resistance (HOMA) and Quantitative Insulin Sensitivity Check Index (QUICKI) will be calculated based on suggested formulas [33, 34]

Blood pressure assessment
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be measured after 5 min of rest with a mercury sphygmomanometer from the patient’s right hand while sitting. Patients should not drink, exercise or smoke for one hour prior to blood pressure assessment. They must also have an empty bladder before measuring their blood pressure. Blood pressure will be taken twice, 5 min apart, while the patient is at rest. Systolic blood pressure is equivalent to the pressure measured after hearing the first korotkoff sound, and diastolic blood pressure is equivalent to the pressure measured when the korotkoff sound disappears. The mean of the two measurements will be considered as systolic and diastolic blood pressure.

Anthropometric assessments
To assess height, the person must be standing and barefoot with an accuracy of 0.5 cm. Weight will be measured using a digital scale with a minimum of clothing and barefoot with an accuracy of 100 gr. Waist circumference will be measured using a tape measure in the middle of the distance between the super iliac bone and the last rib with an accuracy of 0.5 cm. BMI will also be obtained by dividing weight in kilograms by height squared in meters [35].

Other variables assessments
A general questionnaire will be used to collect information about participants’ age, sex, marital status (single / married), education (yes/no), supplement use (yes/ no), medical history, tobacco use (non-smoker /smoking history/smoker), occupation, history of drug use.

Statistical analysis
In this study, all analyses will be done using SPSS software version 26. Normal distribution of data will be assessed by the application of Kolmogorov–Smirnov test. In case of a non-normal distribution, we will apply logarithmic transformation. Results will be reported as mean± standard deviations (SD) or medians (interquartile ranges). General characteristics and dietary intake of individuals between the two groups will be compared using independent t-test and chi-square test as needed. Repeated measure analysis of variance (RM-ANOVA) will be used to examine the effects of probiotic yogurt consumption on outcome variables, where we will examine the effects of time, intervention as well as time-group interaction effects. In this analysis, baseline values of outcome variables will be controlled for. We will also perform post hoc tests after ANOVA analysis to examine the variables between study groups. In case of any difference between the two groups in terms of dietary intakes (other than the intervention) and physical activity throughout the study, these differences will be adjusted for in the analysis to reach an independent effect of intervention on study outcomes. Statistical significance will be set to 0.05.

Ethics and dissemination
This clinical trial study was confirmed by the ethics committee of Tehran University of Medical Sciences (code: IR.TUMS.MEDICINE.REC.1399.1006). Furthermore, it was registered in the Iranian Registry of Clinical Trials (www.irct.ir) at 2021-04-19 (code: IRCT20210201050210N1).
Trial status
The recruitment started on December 2021.

Discussion
NAFLD is an important public health issue due to its high global prevalence [31]. It is a clinical syndrome from simple steatosis to cirrhosis, which is associated with insulin resistance, lipotoxicity, inflammation and obesity [31]. Changes in the composition of gut microbiota, called dysbiosis, are strongly associated with the development and progression of NAFLD [31]. Probiotics play an important role in modulating intestinal bacterial flora and modifying intestinal permeability [31]. Furthermore, the production of short-chain fatty acids by probiotics during fermentation can affect inflammatory, antioxidant, and gene expression pathways, through which they might prevent the progression of liver damage [31].

Previous investigations have reported that consuming probiotic yogurt improves lipid profile, glycemic variables, liver enzyme levels, and steatosis in patients with NAFLD. We are aware of no study examining the effect of probiotic yogurt on liver fibrosis [31]. In addition, earlier studies have mostly applied ultrasound, which is a less accurate method than the fiber scan, to estimate liver fat. Therefore, the aim of our study would be to evaluate the effect of probiotic yogurt consumption on liver enzymes, steatosis and liver fibrosis in patients with NAFLD. Through this investigation and in case of finding an appropriate effect, we would introduce an efficient and cost-effective method to take benefit of probiotics in patients with fatty liver.

Despite several strengths of our study protocol including stratified permuted block randomization and double-blind, placebo-controlled design and conducting the study on newly diagnosed NAFLD patients by fibroscan, some limitations must also be taken into account: We will examine the compliance in this study through collecting dietary intake information by questionnaires. Due to limited funding, we are unable to examine gut microbiota and serum trimethylamine N-oxide (TMAO) as a biomarker for assessment of compliance in this study. We also use probiotic strains available in the food market and did not focus on specific strains that might have different effects. Future studies should examine the effect of foods fortified with specific probiotic strains on steatosis and fibrosis in patients with NAFLD. In addition, another concern might be a limited duration of intervention in this study which would be for 12 weeks. Although one might assume this time period too short for our intervention to affect liver fibrosis, other studies have applied almost the same duration for assessing the effect of intervention of fibrosis among patients with NAFLD.

Abbreviations
NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; BMI: Body mass index; ELISA: Enzyme-linked immuno-sorbent assay; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; METs: Metabolic equivalents; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance; QUICKI: Quantitative Insulin Sensitivity Check Index; RCT: Randomized clinical trial; SD: Standard deviation; SES: Socioeconomic status; TC: Total cholesterol; TG: Triglyceride; WC: Waist circumference; CAP: Controlled attenuation parameter; TMAO: Trimethylamine N-oxide.

Acknowledgements
We would like to thank all participants who will be involved in this trial.

Authors’ contributions
SEM, KJ and AE contributed to conception and study design. AAS contributed to drafting proposal. All authors had a significant contribution in developing the study methodology. SEM, FD and SMA contributed to data collection, data entry and data analysis. SEM, FD and AE drafted the manuscript. All authors had a significant contribution in finalizing the first draft of the manuscript. AE supervised the whole study. All authors read and approved the final manuscript.

Funding
This study was financially supported by a grant from Tehran University of Medical Sciences (TUMS), Tehran, Iran. Grant number: 99-3-212-5085. The funders have no role in the design of the trial, procedures, intervention, collection, evaluation, and data analysis.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
This clinical trial study was confirmed by the ethics committee of Tehran University of Medical Sciences (code: IR.TUMS.MEDICINE.REC.1399.1006). Furthermore, it was registered in the Iranian Registry of Clinical Trials (www.ictrc. ir) at 2021-04-19 (code: IRTC20210201050210N1). All participants will read the terms and conditions written in an informed consent and written informed consent will be obtained from participants before participation in the research project.

Consent for publication
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Competing interests
The authors have no competing of interests to declare.

Author details
1 Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran. 2Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. 3Baqiyatallah Research Center for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, Tehran, Iran. 4Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, P.O. Box 14155-6117, Tehran, Iran. 5Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran. 6 Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. 7 Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.

Received: 27 October 2021 Accepted: 21 February 2022
Published online: 07 March 2022
References

1. Elshaghabee FM, Rokana N, Panwar H, Heller KJ, Schrezenmeir J. Probiotics as a dietary intervention for reducing the risk of nonalcoholic fatty liver disease. In: Arora D, Sharma C, Jaglan S, Lichtfouse E, editors. Pharmaceuticals from microbes. Springer; 2019. p. 207–23.

2. Rozman D. From nonalcoholic fatty liver disease to hepatocellular carcinoma: a systems understanding. Springer. 2014.

3. Bellanti S, Scaglioni F, Marino M, Bedogni G. Epidemiology of nonalcoholic fatty liver disease. Dig Dis. 2010;28(1):153–61.

4. Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Dienstag J. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672–82.

5. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.

6. Eslami L, Merat S, Nasser‑Moghaddam S. Treatment of non‑alcoholic fatty liver disease (NAFLD): a systematic review. Middle East J Dig Dis (MEJDD). 2009;12(2):89–99.

7. Dowman J, Armstrong M, Tomlinson J, Newsome P. Current therapeutic strategies in non‑alcoholic fatty liver disease. Diabetes Obes Metab. 2011;13(8):692–722.

8. Panel AA, Torres DM, Harrison SA. Effect of weight loss on nonalcoholic fatty liver disease (NAFLD). J Hepatol. 2017;67(1):101.

9. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, DeSimone C, Sony X, Diehl AM. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2000;32(2):343–50.

10. Lata J, Jurankova J, Kopacova M, Vitek P. Probiotics in hepatology. World J Gastroenterol WJG. 2011;17(24):2890.

11. Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci. 2014;97(12):7386–93.

12. Kobyliak N, Abenavoli L, Mykhalchyshyn G, Kononenko L, Boccuto L, Kyrienko D, Dynnyk O. A multi‑strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial. JGLD. 2018;27:41–9.

13. Elshaghabee FM, Rokana N, Panwar H, Heller KJ, Schrezenmeir J. Probiotic therapy in patients with nonalcoholic steatohepatitis. Hepatology. 2017;65(6):S31–7.

14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low‑density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.

15. Asgharian A, Askari G, Esmailzade A, Feizi A, Mohammadi V. The effect of probiotics on liver enzymes, cytokine, adiponectin and HOMA‑IR. Diabetes Metab Syndr. 2012;6(3):157–62.

16. Ghahramani S, Razmpoosh E, Shidfar F. Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in nonalcoholic fatty liver disease. EXCLI J. 2017;16:278.

17. Kobyliak N, Abenavoli L, Mykhalchyshyn G, Kononenko L, Boccuto L, Kyrienko D, Dynnyk O. A multi‑strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial. JGLD. 2018;27:41–9.

18. Kobyliak N, Abenavoli L, Mykhalchyshyn G, Kononenko L, Boccuto L, Kyrienko D, Dynnyk O. A multi‑strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial. JGLD. 2018;27:41–9.

19. Kobyliak N, Abenavoli L, Mykhalchyshyn G, Kononenko L, Boccuto L, Kyrienko D, Dynnyk O. A multi‑strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial. JGLD. 2018;27:41–9.